VACC vs. PYXS, STTK, PRLD, ABEO, GLSI, TRVI, VTYX, BMEA, GBIO, and GTHX
Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Pyxis Oncology (PYXS), Shattuck Labs (STTK), Prelude Therapeutics (PRLD), Abeona Therapeutics (ABEO), Greenwich LifeSciences (GLSI), Trevi Therapeutics (TRVI), Ventyx Biosciences (VTYX), Biomea Fusion (BMEA), Generation Bio (GBIO), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Vaccitech (NASDAQ:VACC) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Vaccitech and Vaccitech both had 2 articles in the media. Vaccitech's average media sentiment score of 0.86 beat Pyxis Oncology's score of 0.44 indicating that Vaccitech is being referred to more favorably in the media.
26.1% of Vaccitech shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 6.0% of Vaccitech shares are held by company insiders. Comparatively, 9.3% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Vaccitech has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Pyxis Oncology received 3 more outperform votes than Vaccitech when rated by MarketBeat users. Likewise, 80.00% of users gave Pyxis Oncology an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.
Vaccitech presently has a consensus target price of $7.63, indicating a potential upside of 456.57%. Pyxis Oncology has a consensus target price of $8.80, indicating a potential upside of 126.80%. Given Vaccitech's higher possible upside, research analysts plainly believe Vaccitech is more favorable than Pyxis Oncology.
Pyxis Oncology has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Pyxis Oncology's return on equity.
Summary
Pyxis Oncology beats Vaccitech on 9 of the 16 factors compared between the two stocks.
Get Vaccitech News Delivered to You Automatically
Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccitech Competitors List
Related Companies and Tools
